Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
By Dean Seal
Novartis said federal regulators have approved its Lutathera therapy as a treatment for pediatric patients with certain gastroenteropancreatic neuroendocrine tumors.
The Swiss pharmaceutical company said Tuesday that the Food and Drug Administration has approved the therapy for the treatment of patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
The approval makes Lutathera the first therapy that has been specifically reviewed and approved for use in pediatric patients with gastroenteropancreatic neuroendocrine tumors, Novartis said.
The approval was based on a trial that reported a safety profile for Lutathera that was consistent with an adult population in a previous study that ultimately got the therapy approved for adult patients.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2024 14:18 ET (18:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase